Skip to content

Author

G. Sampogna

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Differential associations of inflammatory-metabolic markers with depressive symptom dimensions: Towards a clinical phenotyping of immune-metabolic depression.

BACKGROUND Depression is increasingly conceptualized as a biologically heterogeneous condition, with immune-inflammatory and metabolic dysregulation implicated in specific symptom dimensions rather than overall depressive severity. However, it remains unclear whether different combinations of inflammatory and metabolic burden define distinct clinical depressive phenotypes. METHODS In this cross-sectional multicenter study on major depressive episodes (MDE), inflammatory and metabolic burden were indexed by C-reactive protein (CRP) and a composite continuous metabolic syndrome score (cMetS). Participants were classified into four immune-metabolic profiles based on the combination of high/low CRP status and high/low metabolic burden. Somatic symptoms, anhedonia, subjective cognitive complaints, and objective cognitive performance were assessed using standardized psychometric and neuropsychological measures. Associations were examined using covariance and multivariable regression models, including four-category profiles and CRP-cMetS interaction terms, with sensitivity analyses using continuous biomarkers. RESULTS Among 221 patients, immune-metabolic profiles differed for somatic symptoms (p = 0.001; η²p = 0.079), anhedonia (p = 0.006; η²p = 0.065), and cognition (Digit-Symbol-Substitution Test [DSST]: p = 0.039; η²p = 0.042). In regression models, the High CRP/High cMetS group was associated with greater somatic symptom burden (β = 5.10, p = 0.001) and poorer cognitive performance (DSST: β = -7.43, p = 0.036; Trail-Making Test-B: β = 41.44, p = 0.008), whereas the High CRP/Low cMetS profile was selectively associated with greater anhedonia (β = 2.93, p < 0.001). Significant CRP×cMetS interactions emerged for anhedonia (p = 0.023). Sensitivity analyses using continuous biomarkers showed convergent results. CONCLUSIONS These findings suggest that distinct combinations of inflammatory and metabolic burden may characterize partly distinct depressive phenotypes across hedonic, somatic, and cognitive domains, supporting the relevance of integrated immune-metabolic profiling for biologically informed stratification and potentially more targeted therapeutic approaches.

M. Di Nicola, M. Pepe, A. Aguglia et al. · 0 citations
Case report Open access Jul 2026

Treatment of obesity with liraglutide in bipolar disorder: a case report

Bipolar disorder (BD) is a chronic, severe mental illness frequently complicated by metabolic disturbances such as obesity, insulin resistance and dyslipidaemia. We report the case of a 57-year-old man with Bipolar I Disorder and class III obesity (BMI 47.7 Kg/m²) whose mood episodes were tightly linked to weight fluctuations. patients’ psychiatric history began in 1986 with a manic episode and recurrent depressive and manic relapses over nearly four decades, often provoked by weight‐loss attempts. In February 2024, he was admitted for initiation of liraglutide under close psychiatric monitoring, given prior episodes of mania triggered by dietary interventions. At baseline, he exhibited moderate illness severity (CGI = 4), insulin resistance (HOMA-IR = 6.19), dyslipidaemia and sedentary habits. Liraglutide was titrated from 0.6 mg to 1.8 mg over three weeks. During the weight-loss intervention, and temporally after liraglutide titration to 1.8 mg/day, he developed a manic episode (YMRS = 30), prompting an increase in risperidone and addition of gabapentin alongside continuation of mood stabilizers. His manic symptoms remitted within one week, allowing discharge with liraglutide 1.8 mg, risperidone 3 mg, valproic acid and lamotrigine. Over subsequent outpatient follow-up at the target liraglutide dose (3 mg/day), he lost 6.5 kg more (total Δ weight = − 7 kg), his HOMA-IR improved to 5.78 and glycemic and lipid parameters stabilized without further mood destabilization. This case illustrates the bidirectional interplay between metabolic regulation and mood stability in BD, highlights the need for close psychiatric monitoring during structured weight-loss interventions in clinically vulnerable patients, and supports integrated multidisciplinary care when initiating anti-obesity treatments in patients with severe mental illness.

S. Cipolla, Giovanni Vasca, Daniele De Francesco et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.